Abrysvo Vaccine Respiratory Syncytial Virus (RSV) Vaccine

ABRYSVO (RSV) Vaccine

Walk-ins are welcome, but appointments are served first.

Who We Vaccinate

ABRYSVO is FDA-approved to help prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60+.

Priority groups include:

  • Adults 75+
  • Adults 60–74 at increased risk (chronic heart or lung disease, weakened immune system, severe obesity, severe diabetes, or residents of nursing homes/long-term care).

What Is RSV?

RSV is a highly contagious virus that infects the lungs and respiratory tract. It can cause more serious illness such as bronchiolitis and pneumonia, especially in vulnerable groups.

ABRYSVO (RSV) Vaccine